Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Penny Stocks

ViewRay’s Final Chapter: Liquidation and Delisting Seal Company’s Fate

Dieter Jaworski by Dieter Jaworski
November 16, 2025
in Penny Stocks, Pharma & Biotech, Turnaround
0
ViewRay Stock
0
SHARES
134
VIEWS
Share on FacebookShare on Twitter

The curtain is closing on ViewRay as the company enters the final stage of its corporate existence. With the bankruptcy proceedings transitioning to Chapter 7 liquidation, the complete dissolution of the business is now underway. The company’s shares have been relegated to over-the-counter trading, where they’re valued at a mere $0.002.

From Restructuring to Complete Liquidation

What began as a Chapter 11 restructuring effort has now culminated in Chapter 7 liquidation as of October 2023. This procedural shift represents the definitive move away from rehabilitation attempts toward complete corporate dissolution. The company is currently liquidating all remaining assets to satisfy creditor claims while ceasing all business operations entirely.

Final Financial Reporting

Today marks the release of ViewRay’s final quarterly report as an insolvent entity. Investors shouldn’t expect traditional operational metrics or performance indicators. Instead, this concluding financial statement will serve as a liquidation progress report, documenting remaining assets against outstanding liabilities.

Should investors sell immediately? Or is it worth buying ViewRay?

OTC Trading with Minimal Value

Following its removal from the Nasdaq exchange, ViewRay now trades exclusively on the over-the-counter market under the ticker symbol VRAYQ. This market downgrade has resulted in significantly reduced liquidity and diminished market transparency. The current share price of $0.002 underscores the company’s dire financial condition.

  • Complete asset liquidation under Chapter 7 bankruptcy
  • Over-the-counter trading under symbol VRAYQ
  • Share value at $0.002
  • Final financial report scheduled for release today

Technical Assessment Points to Total Loss

Technical analysis presents a clear picture: the current signal registers as “Strong Sell.” Moving averages and other technical indicators uniformly reflect the company’s terminal condition. Any position in ViewRay shares must be considered highly speculative with substantial risk of complete capital loss.

ViewRay’s corporate destiny appears sealed. The process now focuses exclusively on monetizing remaining assets for creditor benefit. Shareholders face minimal prospects of recovery as the liquidation process advances toward its conclusion.

Ad

ViewRay Stock: Buy or Sell?! New ViewRay Analysis from February 8 delivers the answer:

The latest ViewRay figures speak for themselves: Urgent action needed for ViewRay investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

ViewRay: Buy or sell? Read more here...

Tags: ViewRay
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock
Analysis

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Next Post
iShares MSCI EAFE ETF Stock

Expanding Your Investment Horizons with the iShares MSCI EAFE ETF

Vapotherm Stock

Vapotherm Secures Key Military Authorization for Respiratory Technology

Stag Industrial Stock

STAG Industrial Shares Surge on Strong Earnings and Analyst Upgrades

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com